JP4762552B2 - 診断用および治療用標的としてのsgk1 - Google Patents
診断用および治療用標的としてのsgk1 Download PDFInfo
- Publication number
- JP4762552B2 JP4762552B2 JP2004569000A JP2004569000A JP4762552B2 JP 4762552 B2 JP4762552 B2 JP 4762552B2 JP 2004569000 A JP2004569000 A JP 2004569000A JP 2004569000 A JP2004569000 A JP 2004569000A JP 4762552 B2 JP4762552 B2 JP 4762552B2
- Authority
- JP
- Japan
- Prior art keywords
- sgk1
- expression
- disease
- antibody
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Description
したがって、本発明における目的は、独立請求項1、6、7、22、26および28の主題によって達成される。好ましい実施形態が従属請求項で特定されている。これにより、これら請求項全ての内容は、これらを参照することによって明細書中に組み入れられる。
図1において、最高値の%で表した凝固促進活性を、カルシウム再添加後の時間に対してプロットしてある。図1に関わる実験において、ヒト血管平滑筋細胞(HAOSMC)の凝固促進活性は、カルシウム再添加した貧血小板血漿(PPP)における凝固プロセス中のトロンビン形成を測定することによって測定した(Beguin S、Lidhout T、Hemker HC:Throm.Haemost.61:25〜29頁、1998年)。このために、集密状態の血管平滑筋細胞を無血清培地で24時間保ち、その後HEPESタイロード溶液で3回洗い、その後にヒトPPPでインキュベートした。トロンビンの形成は、インキュベーション培地に16.7mMのCaCl2を添加することによって誘発した。それぞれの場合において、20μlの上清を1分から2分毎に取り除き、取り除いた容積中でのトロンビンの形成を、染料S−2238(Haemochrom Diagnostica)を用いて測定した。光学濃度を、分光光度計(Uvikon、Contron−instruments)において405nmで測定した。平滑筋細胞における、表面凝固推進活性の膜結合組織因子の利用可能性への依存度を、ヒト組織因子に対する中和抗体(Mab# 4508;American Diagnostica;PPPへのカルシウム再添加前の20分間にわたり10μg/ml)を用いて示した。
Claims (11)
- TF(組織因子)の活性障害に関係する疾患を診断するための診断用キットを調整することを目的とした、真核生物細胞におけるsgk1の発現および/または機能を検出するための、sgk1に対する少なくとも1種の抗体、ポリメラーゼ連鎖反応(PCR)においてsgk1の特定のDNA断片を増幅するために使用できるオリゴヌクレオチド、またはストリンジェントな条件でsgk1のヌクレオチド配列とハイブリダイズすることができるポリヌクレオチドの使用であって、
前記疾患が、凝固障害および/または肺高血圧症であることを特徴とする使用。 - 前記抗体が、sgk1における変異の検出に適していることを特徴とする、請求項1に記載の使用。
- 前記抗体が、ヌクレオチド多型(SNPs)および/または挿入の検出に適していることを特徴とする、請求項1または2に記載の使用。
- TFの活性障害に関係する疾患を治療するための医薬品または製薬組成物を生産することを目的とした、真核生物細胞におけるsgk1の発現および/または機能を阻害するためのケレリトリン、またはそれらの類似体の1つの使用であって、
前記疾患が、凝固障害および/または肺高血圧症であることを特徴とする使用。 - TFの活性障害に関係する疾患を治療するための医薬品または製薬組成物を生産することを目的とした、真核生物細胞におけるsgk1の発現および/または機能を阻害するためのSB203580の使用であって、
前記疾患が、凝固障害、糖尿病性血管症、糖尿病性細小血管症および/または肺高血圧症であることを特徴とする使用。 - TFの活性障害に関係する疾患を治療するための医薬品または製薬組成物を生産することを目的とした、真核生物細胞におけるsgk1の発現および/または機能を阻害するためのSB202190の使用であって、
前記疾患が、凝固障害、糖尿病性血管症、糖尿病性細小血管症、肺高血圧症および/または動脈硬化症であることを特徴とする使用。 - 前記凝固障害が遺伝性の凝固障害であることを特徴とする請求項1から6のいずれかに記載の使用。
- 前記凝固障害が後天性の凝固障害であることを特徴とする請求項1から6のいずれかに記載の使用。
- 凝固障害および/または肺高血圧症をインビトロで診断を補助する方法であって、
sgk1に対する抗体、ポリメラーゼ連鎖反応(PCR)においてsgk1の特定のDNA断片を増幅することができるオリゴヌクレオチド、またはストリンジェントな条件でsgk1のヌクレオチド配列とハイブリダイズすることができるポリヌクレオチドを用い、患者から採取した生体試料においてsgk1の発現および/または機能を定量的に検出する方法。 - 前記抗体が、sgk1における特定の変異を検出するために用いられることを特徴とする、請求項9に記載の方法。
- 前記抗体が、sgk1におけるヌクレオチド多型および/または挿入を検出するために用いられることを特徴とする、請求項9または10に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2003/002163 WO2004079003A1 (de) | 2003-03-03 | 2003-03-03 | Sgk1 als diagnostisches und therapeutisches target |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006518992A JP2006518992A (ja) | 2006-08-24 |
JP4762552B2 true JP4762552B2 (ja) | 2011-08-31 |
Family
ID=32946817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004569000A Expired - Fee Related JP4762552B2 (ja) | 2003-03-03 | 2003-03-03 | 診断用および治療用標的としてのsgk1 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20070059695A1 (ja) |
EP (1) | EP1613766A1 (ja) |
JP (1) | JP4762552B2 (ja) |
KR (2) | KR20110005747A (ja) |
CN (1) | CN100529101C (ja) |
AU (1) | AU2003215623B2 (ja) |
BR (1) | BR0318166A (ja) |
CA (1) | CA2517958A1 (ja) |
MX (1) | MXPA05009292A (ja) |
WO (1) | WO2004079003A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007527875A (ja) * | 2004-03-11 | 2007-10-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 線維症を抑制するための方法 |
DE102008010363A1 (de) | 2008-02-18 | 2009-08-20 | Lang, Florian, Prof. Dr.med. | Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen |
DE102008010361A1 (de) | 2008-02-18 | 2009-08-20 | Merck Patent Gmbh | sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen |
DE102008010362A1 (de) | 2008-02-18 | 2009-08-20 | Florian Prof. Dr. Lang | Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen |
DE102009040879B4 (de) * | 2009-09-09 | 2012-12-06 | Andreas Hettich Gmbh & Co. Kg | Verfahren zur Bestimmung der Gerinnungszeit |
WO2012158866A2 (en) | 2011-05-19 | 2012-11-22 | The Johns Hopkins University | Treatment of autoimmune disorders and infections using antagonists of sgk1 activity |
KR102331240B1 (ko) | 2019-03-21 | 2021-11-29 | 재단법인대구경북과학기술원 | Sgk3 유전자를 이용한 뇌신경계 질환의 진단 및 치료 |
CN116047066B (zh) * | 2022-07-19 | 2024-02-20 | 广州国家实验室 | Sgk1作为靶点在制备诊断、预防、治疗冠状病毒所致疾病的产品中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061039A2 (en) * | 1998-05-22 | 1999-12-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel composition for modulating ischemic cell death |
JP2001106691A (ja) * | 1989-07-25 | 2001-04-17 | Goedecke Ag | インドロカルバゾールおよびその使用 |
WO2001037837A1 (en) * | 1999-11-23 | 2001-05-31 | Smithkline Beecham Corporation | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
WO2002074987A2 (de) * | 2001-03-21 | 2002-09-26 | Florian Lang | Quantitative diagnostische analyse der hypertonie |
WO2002083704A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
JP2002542196A (ja) * | 1999-04-20 | 2002-12-10 | フローリアン・ラング | 細胞容量調節ヒトキナーゼh−sgkのインヒビター含有医薬 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242397A (en) * | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
EP0711556A1 (de) * | 1994-11-09 | 1996-05-15 | Ciba-Geigy Ag | Intravenöse Lösungen für ein Staurosporinderivat |
DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
US20050064501A1 (en) * | 1999-04-20 | 2005-03-24 | Prof. Dr. Med. F. Lang | Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk |
US6416759B1 (en) * | 1999-09-30 | 2002-07-09 | The Regents Of The University Of California | Antiproliferative Sgk reagents and methods |
US6759410B1 (en) * | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
-
2003
- 2003-03-03 CA CA002517958A patent/CA2517958A1/en not_active Abandoned
- 2003-03-03 EP EP03816137A patent/EP1613766A1/de not_active Withdrawn
- 2003-03-03 JP JP2004569000A patent/JP4762552B2/ja not_active Expired - Fee Related
- 2003-03-03 KR KR1020107029753A patent/KR20110005747A/ko not_active Application Discontinuation
- 2003-03-03 CN CNB03826398XA patent/CN100529101C/zh not_active Expired - Fee Related
- 2003-03-03 BR BRPI0318166-9A patent/BR0318166A/pt not_active IP Right Cessation
- 2003-03-03 KR KR1020057016434A patent/KR101032281B1/ko not_active IP Right Cessation
- 2003-03-03 WO PCT/EP2003/002163 patent/WO2004079003A1/de active Application Filing
- 2003-03-03 MX MXPA05009292A patent/MXPA05009292A/es active IP Right Grant
- 2003-03-03 AU AU2003215623A patent/AU2003215623B2/en not_active Ceased
- 2003-03-05 US US10/547,746 patent/US20070059695A1/en not_active Abandoned
-
2011
- 2011-12-09 US US13/315,850 patent/US20120149765A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001106691A (ja) * | 1989-07-25 | 2001-04-17 | Goedecke Ag | インドロカルバゾールおよびその使用 |
WO1999061039A2 (en) * | 1998-05-22 | 1999-12-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel composition for modulating ischemic cell death |
JP2002542196A (ja) * | 1999-04-20 | 2002-12-10 | フローリアン・ラング | 細胞容量調節ヒトキナーゼh−sgkのインヒビター含有医薬 |
WO2001037837A1 (en) * | 1999-11-23 | 2001-05-31 | Smithkline Beecham Corporation | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
WO2002074987A2 (de) * | 2001-03-21 | 2002-09-26 | Florian Lang | Quantitative diagnostische analyse der hypertonie |
WO2002083704A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
Also Published As
Publication number | Publication date |
---|---|
US20120149765A1 (en) | 2012-06-14 |
JP2006518992A (ja) | 2006-08-24 |
CN1771330A (zh) | 2006-05-10 |
WO2004079003A1 (de) | 2004-09-16 |
KR101032281B1 (ko) | 2011-05-06 |
KR20110005747A (ko) | 2011-01-18 |
AU2003215623A1 (en) | 2004-09-28 |
MXPA05009292A (es) | 2006-03-21 |
CN100529101C (zh) | 2009-08-19 |
BR0318166A (pt) | 2006-04-04 |
EP1613766A1 (de) | 2006-01-11 |
KR20060015467A (ko) | 2006-02-17 |
US20070059695A1 (en) | 2007-03-15 |
CA2517958A1 (en) | 2004-09-16 |
AU2003215623B2 (en) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120149765A1 (en) | Sgk1 as diagnostic and therapeutic target | |
Qiao et al. | Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis | |
US20080317735A1 (en) | Pharmaceutical preparation with RNA as hemostasis cofactor | |
Xu et al. | Factor VII deficiency impairs cutaneous wound healing in mice | |
US20030073632A1 (en) | Methods of treating diseases with activated protein c | |
Zhang et al. | Hypoxia-specific upregulation of calpain activity and gene expression in pulmonary artery endothelial cells | |
Pérez-Ruiz et al. | Regulation by nitric oxide of endotoxin-induced tissue factor and plasminogen activator inhibitor-1 in endothelial cells | |
Beaulieu et al. | Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor‐1 cycle | |
US20060121465A1 (en) | Sgk and nedd used as diagnostic and therapeutic targets | |
Fu et al. | Overexpression of integrin β1 inhibits proliferation of hepatocellular carcinoma cell SMMC‐7721 through preventing Skp2‐dependent degradation of p27 via PI3K pathway | |
US20130267584A1 (en) | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics | |
Yin et al. | Antisense oligodeoxynucleotide against tissue factor inhibits human umbilical vein endothelial cells injury induced by anoxia-reoxygenation | |
EP1074634B1 (en) | Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease | |
WO2001072328A2 (en) | Methods of treating diseases with activated protein c | |
KR20050114214A (ko) | 백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도 | |
DE10149393A1 (de) | sgk1 als diagnostisches und therapeutisches target | |
RU2331072C2 (ru) | sgk1 В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОЙ И ТЕРАПЕВТИЧЕСКОЙ МИШЕНИ | |
JP2004516038A (ja) | 慢性炎症性気道疾患の炎症性状態に陽性の影響を与える物質を同定するための方法 | |
EP3696281A1 (en) | Arginase as biomarker and drug target for pcos | |
Susarla et al. | Regulation of plasminogen activators in human thyroid follicular cells and their relationship to differentiated function | |
JP2004516837A (ja) | 慢性炎症性気道疾患の炎症性状態に陽性の影響を与える物質を同定するための方法 | |
Baran et al. | MRCKα/β positively regulates Gli protein activity | |
KR20050016494A (ko) | 진단 및 치료 표적으로 사용되는 sgk 및 nedd | |
Mammen | α2-Antiplasmin Deficiency | |
WO2015044333A1 (en) | Methods for treating and diagnosing heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090420 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090427 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090518 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090617 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090624 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090717 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090717 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091209 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100302 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100302 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110316 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110401 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110608 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140617 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |